Every 10-Q that Collegium Pharmaceutical, Inc. (COLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COLL filings page.
Collegium Pharmaceutical reported modest top-line growth but weaker profitability for the quarter ended June 30, 2026. Net product revenues were $199,878 for the quarter and $393,398 for the first six months, up from the prior-year periods. Gross profit reached $110,292 in the quarter, but higher selling, general and administrative expense of $106,594, along with $62,953 of intangible amortization, reduced income from operations to $3,698. After net interest expense and taxes, the company posted a quarterly net loss of $15,051 and a six‑month net loss of $555, or $(0.46) per diluted share in the quarter.
The balance sheet expanded following the Azstarys acquisition, with total assets of $2,135,790, including $1,186,084 of net intangible assets and $190,177 of goodwill. Total liabilities were $1,823,881, driven by term notes payable of $797,824, convertible senior notes of $238,733, a deferred royalty obligation of $121,357 and $38,525 of contingent consideration. Total purchase consideration for Azstarys was $706,253, funded by $355,600 of cash on hand and a $300,000 delayed draw term loan. Operating cash flow was $128,436 for the six months, while investing outflows of $500,964 and financing inflows of $270,747 led to cash, cash equivalents and restricted cash of $150,377 at period end.
Collegium Pharmaceutical reported significantly stronger quarterly results. For the three months ended March 31, 2026, product revenues, net were $193.5 million, up from $177.8 million a year earlier, driven by growth across Belbuca, Xtampza ER, Jornay PM and Symproic. Net income rose to $14.5 million from $2.4 million, with diluted earnings per share increasing to $0.40 from $0.07.
Cash, cash equivalents and restricted cash totaled $289.6 million, while total debt, including term notes and convertible senior notes, remained substantial. Collegium also signed an agreement to acquire AZSTARYS® for $650 million in cash plus up to $135 million in milestones, aiming to further expand its neuropsychiatry portfolio following the Ironshore acquisition and Jornay PM integration.
Collegium Pharmaceutical (COLL) reported stronger Q3 2025 results. Product revenues, net reached $209,361 (up from $159,301), and net income was $31,507 (vs. $9,335). Gross profit rose to $129,171 with total operating expenses at $67,084. Diluted EPS was $0.84.
For the nine months, product revenues, net were $575,118 (vs. $449,500) and operating cash flow was $206,275. Cash and cash equivalents increased to $150,096, with marketable securities at $135,767. By product in Q3: Belbuca $58,255; Xtampza ER $50,478; Jornay PM $41,802; Nucynta IR $31,988; Nucynta ER $22,813; Symproic $4,025. Jornay PM growth reflects the Ironshore acquisition, which contributed a $635,000 intangible asset now amortizing over 7.7 years.
Debt included term notes payable of $570,166 (carrying value) and convertible senior notes at $237,950. The deferred royalty obligation tied to Jornay PM carried $122,279, with the royalty rate stepping from 7.4% before July 1, 2025 to 9.7% thereafter through March 2032.